A method of identifying an SCLC patient at risk of disease progression comprising determining the RNA-expression of at least one marker selected from a neuroendocrine marker and/or DLL3 in a fraction of a blood sample of said patient which blood fraction is enriched in circulating tumor cells (CTCs), wherein said at least one marker is indicative of the patient’s prognosis.
Diagnostic tests for circulating tumor cells in ovarian cancer.
Diagnostic tests for circulating tumor cells in ovarian cancer.
Diagnostic tests for circulating tumor cells in breast, ovarian, endometrial and cervical cancer.
Method for quantitative determination of CK19 mRNA-positive cells in a biological sample.
Diagnostic test for early detection of ovarian cancer based on RNA biomarkers and RNA/protein biomarker models.
OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Straße 2, Objekt E
2700 Wiener Neustadt
AUSTRIA
© 2021 OncoLab Diagnostics GmbH
Created by DesignLaden